Compare · DFTX vs SUPN

DFTX vs SUPN

Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Supernus Inc. (SUPN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. DFTX focuses on Medicinal Chemicals and Botanical Products, while SUPN focuses on Biotechnology: Pharmaceutical Preparations.
  • SUPN is the larger of the two at $5.94B, about 1.5x DFTX ($3.88B).
  • Over the past year, DFTX is up 141.1% and SUPN is down 13.1% - DFTX leads by 154.3 points.
  • SUPN has been more active in the news (31 items in the past 4 weeks vs 9 for DFTX).
  • SUPN has more recent analyst coverage (10 ratings vs 8 for DFTX).
PerformanceDFTX+141.13%SUPN-13.13%
2025-11-24+0.00%2026-11-20
MetricDFTXSUPN
Company
Definium Therapeutics Inc.
Supernus Inc.
Price
-
-
Market cap
$3.88B
$5.94B
1M return
-21.27%
-18.95%
1Y return
+141.13%
-13.13%
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
2012
News (4w)
9
31
Recent ratings
8
10
SUPN

Supernus Inc.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc. to conduct a Phase II clinical program for NV-5138 in treatment-resistant depression. The company was founded in 2005 and is headquartered in Rockville, Maryland.

Latest DFTX

Latest SUPN